In spite of the widespread belief that testosterone supplementation increases the risk of atherosclerotic heart disease, evidence to support this premise is lacking. Although supraphysiological doses of testosterone, such as those used by athletes and recreational body builders, decrease plasma high-density lipoprotein (HDL) cholesterol concentrations, replacement doses of testosterone have had only a modest or no effect on plasma HDL in placebo-controlled trials. In epidemiological studies, serum total and free testosterone concentrations have been inversely correlated with intra-abdominal fat mass, risk of coronary artery disease, and type 2 diabetes mellitus. Testosterone administration to middle-aged men is associated with decreased visceral fat and glucose concentrations and increased insulin sensitivity. Testosterone infusion increases coronary blood flow. Similarly, testosterone replacement retards atherogenesis in experimental models of atherosclerosis. However, the long-term risks and benefits of testosterone administration in human immunodeficiency virusinfected men with fat redistribution syndrome have not been studied in randomized clinical trials.
There is a widespread perception that testosterone supplementation adversely affects the plasma lipoprotein profile and increases the risk of atherosclerotic heart disease; this premise is not supported by data [1, 2] . Thus, the long-term consequences of testosterone supplementation on the risk of atherosclerosis progression remain unknown. Although supraphysiological doses of testosterone and nonaromatizable androgens frequently used by body builders undoubtedly decrease plasma high-density lipoprotein (HDL) cholesterol levels [3] [4] [5] [6] [7] , physiological testosterone replacement in older men has been associated with only a modest or no decrease in plasma HDL cholesterol [8] [9] [10] [11] . Cross-sectional studies of middle-aged men [12] [13] [14] have found a direct, rather than an inverse, relationship between serum testosterone levels and plasma HDL cholesterol concentrations, as well as an inverse correlation between serum testosterone levels and visceral fat volume. Testosterone supplementation in middle-aged men who have truncal obesity is associated with a reduction in visceral fat volume, serum glucose concentration, and blood pressure and an improvement in insulin sensitivity [15] [16] [17] . These data suggest that serum testosterone levels in the range that is midnormal for healthy young men are consistent with an optimal cardiovascular risk profile at any age and that testosterone concentrations either above or below the physiologically normal male range may increase the risk of atherosclerotic heart disease. In light of these data, the present review will discuss the rationale for the use of testosterone supplementation in HIV-infected men with fat redistribution syndromes.
HIGH PREVALENCE OF LOW TESTOSTERONE CONCENTRATIONS IN HIV-INFECTED MEN
Although the prevalence of androgen deficiency, defined solely in terms of low testosterone levels, has decreased with the advent of potent antiretroviral therapy, androgen deficiency continues to be a common complication of HIV infection in men.
In an earlier survey of 150 HIV-infected men who attended our HIV clinic in 1997, approximately one-third had serum total and free testosterone levels in the hypogonadal range [18] . Other investigators have reported a similar prevalence of hypogonadism in HIV-infected men during the pre-HAART era [19] [20] [21] [22] [23] [24] [25] [26] [27] . A more recent survey [28] of HIV-infected drug users found the prevalence of low testosterone levels to be 20%. Thus, androgen deficiency continues to be a common occurrence in HIV-infected men.
In our survey, 20% of HIV-infected men with low testosterone levels had elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels and hypergonadotropic hypogonadism [18] . These patients presumably had primary testicular dysfunction. The remaining 80% had either normal or low LH and FSH levels; these men with hypogonadotropic hypogonadism either had a central defect at the hypothalamic or pituitary site or a dual defect involving both the testis and the hypothalamic-pituitary centers. The pathophysiology of hypogonadism in HIV infection is complex and involves defects at multiple levels of the hypothalamic-pituitary testicular axis.
In a recent study, a majority of men with chronic obstructive lung disease had low total and free testosterone levels [29] . Similarly, previous reports have suggested that two-thirds of men with end-stage renal disease have low total and free testosterone concentrations [30] . In a recent study of 39 men undergoing hemodialysis who had end-stage renal disease but not diabetes mellitus, 24 (62%) had serum total and free testosterone levels below the lower limit of the normal male range [31] .
The pathophysiology of hypogonadism in chronic illness is multifactorial; defects exist at all levels of the hypothalamic-pituitarytesticular axis [32] [33] [34] [35] [36] [37] . Malnutrition, mediators and products of the systemic inflammatory response, drugs such as ketoconazole, and metabolic abnormalities produced by the systemic illness all contribute to a decline in testosterone production.
EFFECTS OF SPONTANEOUS AND EXPERIMENTALLY INDUCED ANDROGEN DEFICIENCY ON FAT MASS AND DISTRIBUTION
Seidell et al. [38] examined the relationship between serum free testosterone levels and visceral fat measured by CT scan in healthy men aged 30-70 years. Serum free testosterone levels were inversely correlated with visceral fat mass. However, free testosterone concentrations were measured by a tracer analog method, which is affected by sex hormone-binding globulin (SHBG). Because SHBG is decreased by obesity, it is possible that the apparent relationship between visceral fat and free testosterone is a reflection of the relationship between SHBG and visceral fat volume. Similarly, healthy hypogonadal men have a higher fat mass than age-matched eugonadal controls [39] . Most conclusive information has emerged from the elegant studies of Mauras et al. [40] , who demonstrated that the experimental induction of androgen deficiency in healthy young men by administration of a gonadotropin-releasing hormone (GnRH) agonist is associated with a decrease in fat-free mass and an increase in fat mass. Thus, androgen deficiency, whether it occurs spontaneously or is induced experimentally, is associated with increased fat mass, particularly in the visceral fat compartment.
EFFECTS OF TESTOSTERONE SUPPLEMENTATION ON WHOLE-BODY AND REGIONAL FAT DISTRIBUTION
Many, but not all, studies of testosterone replacement in healthy, young, hypogonadal men have reported a decrease in fat mass after testosterone supplementation (table 1) [41-43, 45, 46] . Studies that recruited lean, young, hypogonadal men have not demonstrated significant changes in fat mass [41] . Marin et al. [15] [16] [17] reported that testosterone supplementation in middle-aged men with low to low-normal testosterone concentrations is associated with a significant reduction in the visceral fat cross-sectional area, plasma insulin levels, and blood glucose concentrations and an improvement in insulin sensitivity. Long-term, placebo-controlled, randomized trials of testosterone replacement in older men have also been in agreement that testosterone replacement in older men with low-normal testosterone concentrations is associated with gains in fat-free mass and a loss of fat mass (table 2) [8-11, 47, 50] .
DOSE-DEPENDENT EFFECTS OF TESTOSTERONE ON WHOLE-BODY AND REGIONAL FAT DISTRIBUTION IN HEALTHY YOUNG MEN
To determine the effects of graded doses of testosterone on regional adipose tissue distribution, we randomized 61 healthy men, aged 18-35 years, to receive 20 weeks of treatment with a long-acting GnRH agonist (to suppress endogenous T secretion) plus 1 of 5 weekly intramuscular doses (25, 50, 125 , 300, or 600 mg) of testosterone enanthate (TE) [51] . Energy and protein intake were standardized. Fat mass was measured by 2205 ‫ע‬ 241 spectively. The change in whole-body fat mass was inversely correlated with testosterone dose and concentration. Wholebody fat mass, measured by underwater weighing and DXA, increased significantly in men who received 25 and 50 mg/week of TE and decreased in those who received 300 and 600 mg/ week. There was a significant reduction in both appendicular and truncal fat at the 300 and 600 mg/week doses but a significant increase at the 25 and 50 mg/week doses. The absolute change in fat mass was not significantly different between the trunk and the appendices. The subcutaneous as well as the intermuscular fat mass decreased significantly in men who received the 300-and 600-mg doses. The absolute changes in subcutaneous and intermuscular fat mass were not significantly different. There was a significant (analysis of variance, P p ) decrease in intra-abdominal fat volume at the 125-mg .006 ( c m 3 decrease) and 600-mg ( cm 3 decrease) 18 ‫ע‬ 41 46 ‫ע‬ 39 doses. The changes in both intra-abdominal and intermuscular fat mass were negatively correlated with testosterone dose. The changes in visceral fat mass were also negatively correlated with serum testosterone concentration. Therefore, changes in testosterone concentration among healthy young men are associated with dose-dependent changes in whole-body fat mass that reflect changes in both the truncal and appendicular fat depots.
TESTOSTERONE EFFECTS ON FAT METABOLISM
Marin et al. [52] studied the uptake and turnover of triglycerides from the peripheral and abdominal subcutaneous fat depots after the administration of labeled oleic acid. In contrast to dihydrotestosterone (DHT) and placebo, testosterone inhibited the uptake of label into the abdominal subcutaneous fat, increased its turnover, and was associated with lower lipoprotein lipase (LPL) activity only in the abdominal subcutaneous fat but not in the femoral subcutaneous fat. Androgens increase insulin-independent glucose uptake [53] and modulate LPL activity [54] .
TESTOSTERONE EFFECTS ON PLASMA LIPIDS
Testosterone effects on plasma lipids depend on the dose, route of administration, and type of androgen (whether it is aromatizable). Supraphysiological doses of androgens, particularly those that are administered orally (nonaromatizable androgens), undoubtedly lower plasma HDL and increase low-density lipoprotein (LDL) cholesterol concentrations [3] [4] [5] [6] [7] . A metaanalysis by Whitsel et al. [55] of 20 studies has shown that healthy hypogonadal men have higher HDL cholesterol and that physiological testosterone replacement lowers HDL modestly, by 4 mg/dL, on average, and total cholesterol by 5 mg/dL and has no effect on plasma LDL or triglycerides. Testosterone supplementation also lowers lipoprotein a and plasminogen activator inhibitor 1 (PAI-1). Lower testosterone levels in men are associated with higher levels of dense LDL particles [56] and prothrombotic factors [57] .
A number of studies have been in agreement that the physiological testosterone replacement of HIV-infected men with weight loss does not significantly affect plasma lipid levels [58] [59] [60] [61] . Similarly, placebo-controlled, randomized controlled trials of testosterone replacement in older men have not demonstrated significant changes in plasma HDL cholesterol concentrations [8] [9] [10] [11] . 
TESTOSTERONE AND INSULIN SENSITIVITY
Cross-sectional epidemiological studies have reported a direct correlation between serum testosterone concentrations and insulin sensitivity [62] . Low testosterone levels are associated with an increased risk of type 2 diabetes mellitus in men [63, 64] . However, the data from intervention studies on the effects of testosterone replacement on insulin sensitivity are conflicting. Marin et al. [15] reported that testosterone administration in replacement doses to middle-aged men with low-normal testosterone levels improves insulin sensitivity and lowers serum insulin levels. However, in a recent dose-response study in which we administered a range of testosterone doses to healthy men, the insulin sensitivity index, measured by a frequently sampled intravenous glucose tolerance test using the Bergman minimal model, did not significantly change across a range of testosterone doses and concentrations that were tested [65] . However, the participants in that study were young and very lean; it is possible that, in middle-aged and older HIV-infected men with higher fat mass, testosterone replacement might improve insulin sensitivity by reducing fat mass. Testosterone effects on insulin sensitivity depend on the dose. For instance, in one study [66] , the effects of surgical castration and testosterone administration on insulin sensitivity were studied in adult male rats using the insulin clamp method. Adult male rats became severely insulin resistant when they were castrated. Physiological testosterone replacement in these castrated rats restored their insulin sensitivity to levels seen in intact rats. Supraphysiological doses of testosterone made the rats insulin resistant again. These beneficial effects of testosterone replacement on insulin sensitivity were independent of free fatty acid concentrations.
EFFECTS OF TESTOSTERONE SUPPLEMENTATION ON INFLAMMATION MARKERS
Testosterone replacement in young men does not affect inflammation markers [66, 67] . Thus, C-reactive protein levels in healthy young men were unaffected by testosterone administration across a range of testosterone doses [66] . In another prospective study of older men, DHT or human chorionic gonadotropin administration did not significantly affect highsensitivity C-reactive protein, soluble vascular cell adhesion molecule-1, or soluble intracellular adhesion molecule levels [67] .
TESTOSTERONE EFFECTS ON COAGULATION AND FIBRINOLYTIC FACTORS
In cross-sectional epidemiological studies, serum testosterone levels have been positively correlated with tissue plasminogen activator and inversely correlated with PAI-1, fibrinogen, a-2 anti-plasmin, and factor VIIc levels [57, 68] . Men with hypogonadism have low baseline fibrinolytic activity, which is accounted for by an increased synthesis of PAI-1. There have been isolated case reports of stroke and deep-vein thrombosis in young men who were taking large amounts of androgenic steroids. However, the results of the intervention studies with testosterone replacement have been less clear; testosterone administration increases the circulating levels of both pro-and anticoagulant factors.
ASSOCIATION OF SERUM TESTOSTERONE LEVELS AND HEART DISEASE
Whether a variation of testosterone levels within the normal range is associated with a risk of coronary artery disease remains unclear. Of the 30 studies reviewed by Alexandersen et al. [2] , 18 reported lower testosterone levels in men with coronary artery disease, 11 found similar testosterone levels in controls and men with coronary artery disease, and 1 found higher levels of dehydroepiandrosterone sulfate. Prospective populationbased studies [2] have not revealed an association between total testosterone levels and cardiovascular mortality. Male survivors of myocardial infarction have lower testosterone levels and higher estradiol:testosterone ratios than age-matched control subjects. Phillips et al. [69] reported an inverse correlation between free testosterone levels and the degree of coronary artery disease in a group of men undergoing coronary angiography. Although the study by English et al. [70] did not find a correlation between plasma androgen levels and the severity of coronary artery disease, others who have used quantitative coronary angiography have found a positive correlation between androgen levels and the degree of coronary disease. Thus, cohort and cross-sectional studies have suggested a neutral or favorable effect of testosterone on coronary heart disease in men [2] .
INTERVENTION STUDIES OF THE EFFECTS OF TESTOSTERONE SUPPLEMENTATION ON CORONARY ARTERY DISEASE
A number of studies conducted in the 1940s reported that testosterone administration improved angina pectoris in men with coronary artery disease [71, 72] . Testosterone infusion acutely improves coronary blood flow in dogs and humans [73, 74] . Testosterone relaxes coronary arteries by opening the largeconductance, calcium-activated potassium channel [75] .
TESTOSTERONE RETARDS ATHEROSCLEROSIS PROGRESSION IN AN ANIMAL MODEL OF ATHEROSCLEROSIS
In a LDL receptor-deficient mouse model of atherosclerosis [68] , orchiectomy was associated with the accelerated formation of early atherosclerotic lesions in the aorta. Testosterone supplementation retards the progression of atherosclerotic lesion, an effect that is blocked by the concomitant administration of an aromatase inhibitor [76] . Testosterone effects on atherosclerosis progression were independent of plasma lipids. These data provide compelling evidence that testosterone, through its conversion to estradiol, can retard the progression of atherosclerosis in this animal model. Prospective studies are needed extend these observations to humans, assess the effects of testosterone on atherosclerosis progression in older men, and determine whether testosterone effects on atherosclerosis are mediated through its conversion to estradiol.
SYNOPSIS
Testosterone supplementation decreases the fat mass in men by inhibiting adipogenic differentiation. Replacement doses of testosterone are associated with a small reduction or no change in plasma HDL cholesterol concentrations. Epidemiological studies have reported an inverse relationship between serum free testosterone concentrations and visceral fat mass and the risk of heart disease and type 2 diabetes mellitus. The hypothesis that physiological testosterone replacement might improve insulin sensitivity and retard atherosclerosis in HIV-infected men with fat redistribution syndrome should be tested in prospective, placebo-controlled, clinical trials.
